Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Trial Profile

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs ONC 201 (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Oncoceutics
  • Most Recent Events

    • 10 Mar 2017 Planned number of patients changed from 30 to 42.
    • 10 Mar 2017 Planned primary completion date changed from 1 Sep 2020 to 8 Mar 2019.
    • 10 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top